{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:12:14Z","timestamp":1777867934697,"version":"3.51.4"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007813","name":"Center for AIDS Research, University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007813","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019610","name":"Center for AIDS Research, University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1PO1HL131477"],"award-info":[{"award-number":["1PO1HL131477"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AI027767-31"],"award-info":[{"award-number":["P30 AI027767-31"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.exphem.2022.09.001","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T02:54:57Z","timestamp":1663210497000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-7204","authenticated-orcid":false,"given":"Sweta B.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-4736","authenticated-orcid":false,"given":"Valeriya","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria R.","family":"Matkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alana M.","family":"Franceski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-2968","authenticated-orcid":false,"given":"Mahmoud A.","family":"Bassal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Welner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.09.001_bib0001","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0002","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.09.001_bib0003","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0004","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.exphem.2022.09.001_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0006","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0007","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0008","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41375-021-01315-0","article-title":"Metabolic alterations mediated by STAT3 promotes drug persistence in CML","volume":"35","author":"Patel","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.001_bib0009","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.09.001_bib0010","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI79196","article-title":"Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells","volume":"126","author":"Zhang","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2022.09.001_bib0011","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0012","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.09.001_bib0013","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.stem.2021.01.018","article-title":"Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms","volume":"28","author":"Tong","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0014","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","article-title":"Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells","volume":"27","author":"Welner","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0016","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0017","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-019-0427-7","article-title":"Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling","volume":"33","author":"Kuepper","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.001_bib0018","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2022.09.001_bib0019","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2022.09.001_bib0020","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1182\/blood.2019004371","article-title":"Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation","volume":"136","author":"Diral","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0021","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-\u03b2-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.09.001_bib0022","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","article-title":"Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation","volume":"122","author":"Gallipoli","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0023","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0024","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.001_bib0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.exphem.2022.09.001_bib0026","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34+\/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin","volume":"97","author":"Herrmann","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2022.09.001_bib0027","first-page":"4787","article-title":"IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients","volume":"7","author":"Zhao","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.exphem.2022.09.001_bib0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.exphem.2017.04.003","article-title":"Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications","volume":"51","author":"Sadovnik","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2022.09.001_bib0029","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0030","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1074\/mcp.M112.021931","article-title":"A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers","volume":"12","author":"Bonardi","year":"2013","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.exphem.2022.09.001_bib0031","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41375-019-0684-5","article-title":"CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy","volume":"34","author":"Kinstrie","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.001_bib0032","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.001_bib0033","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fbioe.2020.00322","article-title":"Cell culture based in vitro test systems for anticancer drug screening","volume":"8","author":"Kitaeva","year":"2020","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.exphem.2022.09.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100730","article-title":"Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome","volume":"53","author":"Cucchi","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.exphem.2022.09.001_bib0035","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.colsurfb.2017.07.051","article-title":"Advances and challenges in stem cell culture","volume":"159","author":"McKee","year":"2017","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.exphem.2022.09.001_bib0036","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3390\/cells8121628","article-title":"Traditional and advanced cell cultures in hematopoietic stem cell studies","volume":"8","author":"Ribeiro-Filho","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.exphem.2022.09.001_bib0037","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/cells8020169","article-title":"Ex vivo expansion of hematopoietic stem cells for therapeutic purposes: Lessons from development and the niche","volume":"8","author":"Tajer","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.exphem.2022.09.001_bib0038","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41551-019-0495-z","article-title":"On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology","volume":"4","author":"Chou","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.exphem.2022.09.001_bib0039","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.celrep.2019.06.008","article-title":"Environmental optimization enables maintenance of quiescent hematopoietic stem cells ex vivo","volume":"28","author":"Kobayashi","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2022.09.001_bib0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-019-1244-x","article-title":"Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation","volume":"571","author":"Wilkinson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.09.001_bib0041","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1191536","article-title":"Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells","volume":"329","author":"Boitano","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.exphem.2022.09.001_bib0042","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1006\/cimm.2001.1895","article-title":"Observation of antigen-dependent CD8+ T-cell\/dendritic cell interactions in vivo","volume":"214","author":"Schaefer","year":"2001","journal-title":"Cellular Immunol"},{"key":"10.1016\/j.exphem.2022.09.001_bib0043","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41596-019-0263-2","article-title":"Long-term ex vivo expansion of mouse hematopoietic stem cells","volume":"15","author":"Wilkinson","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.exphem.2022.09.001_bib0044","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: A comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2022.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2015.04.044","article-title":"Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells","volume":"161","author":"Klein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0046","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.celrep.2019.06.031","article-title":"Mapping distinct bone marrow niche populations and their differentiation paths","volume":"28","author":"Wolock","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2022.09.001_bib0047","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: Computational identification of cell doublets in single-cell transcriptomic data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst"},{"key":"10.1016\/j.exphem.2022.09.001_bib0048","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-020-2503-6","article-title":"Single-cell lineage tracing unveils a role for TCF15 in haematopoiesis","volume":"583","author":"Rodriguez-Fraticelli","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.09.001_bib0049","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: Stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0050","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nm.4310","article-title":"Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia","volume":"23","author":"Kesarwani","year":"2017","journal-title":"Nature Med"},{"key":"10.1016\/j.exphem.2022.09.001_bib0051","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0052","doi-asserted-by":"crossref","first-page":"108880","DOI":"10.18632\/oncotarget.22353","article-title":"Matrine inhibits BCR\/ABL mediated ERK\/MAPK pathway in human leukemia cells","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2022.09.001_bib0053","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/nm.4399","article-title":"Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells","volume":"23","author":"Kuntz","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2022.09.001_bib0054","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.stem.2015.05.003","article-title":"Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions","volume":"17","author":"Pietras","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0055","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0056","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0057","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/onc.2010.67","article-title":"Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming","volume":"29","author":"Zhao","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2022.09.001_bib0058","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","article-title":"Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition","volume":"123","author":"Ng","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0059","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","article-title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","volume":"130","author":"Cheloni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0060","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bcmd.2015.08.002","article-title":"Gene expression profile of circulating CD34+ cells and granulocytes in chronic myeloid leukemia","volume":"55","author":"Cokic","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.exphem.2022.09.001_bib0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2022.09.001_bib0062","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.exphem.2022.09.001_bib0063","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0064","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI45977","article-title":"CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression","volume":"122","author":"Schurch","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2022.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0066","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.stem.2020.04.005","article-title":"Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors","volume":"27","author":"Rothe","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0067","doi-asserted-by":"crossref","first-page":"24326","DOI":"10.1073\/pnas.2009078117","article-title":"Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches","volume":"117","author":"Krenn","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.exphem.2022.09.001_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2019.12.003","article-title":"CD34 and EPCR coordinately enrich functional murine hematopoietic stem cells under normal and inflammatory conditions","volume":"81","author":"Rabe","year":"2020","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2022.09.001_bib0069","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.001_bib0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/s12885-019-5871-2","article-title":"Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia","volume":"19","author":"Herrmann","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.exphem.2022.09.001_bib0071","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1038\/s41375-020-0977-8","article-title":"Therapeutic inhibition of Fc\u03b3RIIb signaling targets leukemic stem cells in chronic myeloid leukemia","volume":"34","author":"Parting","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.001_bib0072","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1084\/jem.20130428","article-title":"Fgd5 identifies hematopoietic stem cells in the murine bone marrow","volume":"211","author":"Gazit","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.exphem.2022.09.001_bib0073","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","article-title":"SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells","volume":"121","author":"Kiel","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0074","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.stem.2007.08.016","article-title":"Limiting factors in murine hematopoietic stem cell assays","volume":"1","author":"Purton","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2022.09.001_bib0075","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2022.09.001_bib0076","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/386177a0","article-title":"Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein","volume":"386","author":"Peeper","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.09.001_bib0077","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","article-title":"Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors","volume":"119","author":"Nieborowska-Skorska","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0078","first-page":"461","article-title":"Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia","volume":"27","author":"Li","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1016\/j.exphem.2022.09.001_bib0079","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0080","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.febslet.2007.02.048","article-title":"Upregulation of the TGFbeta signalling pathway by Bcr-Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia","volume":"581","author":"Moller","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1016\/j.exphem.2022.09.001_bib0081","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1073\/pnas.1017496108","article-title":"An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt\/wingless signaling pathway","volume":"108","author":"Gonsalves","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1016\/j.exphem.2022.09.001_bib0082","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2016-05-714089","article-title":"Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI","volume":"129","author":"Agarwal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.001_bib0083","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2009.12.001","volume":"20","author":"Lane","year":"2010","journal-title":"Leukemia stem cells. Semin Cancer Biol."},{"key":"10.1016\/j.exphem.2022.09.001_bib0084","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1038\/onc.2013.520","article-title":"Stem cell origin of myelodysplastic syndromes","volume":"33","author":"Elias","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2022.09.001_bib0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22006968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X22006968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:12:32Z","timestamp":1777547552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X22006968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":85,"alternative-id":["S0301472X22006968"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.09.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of ISEH -- Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}